Payback? Analysts say Sarepta was blindsided by an FDA rejection driven by regulatory revenge
In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.
In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.